[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563471":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":37,"centralContacts":42,"locations":48,"responsibleParty":67,"collaborators":69,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":26,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":26,"enrollmentInfo":84,"targetDuration":26,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Abiraterone + Dexamethasone","EXPERIMENTAL","Abiraterone acetate plus dexamethasone",[13,14],"Drug: Abiraterone acetate","Drug: Dexamethasone",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm 2: Abiraterone + Dexamethasone + metronidazole","Abiraterone acetate plus dexamethasone plus metronidazole",[13,14,19],"Drug: Metronidazole",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Abiraterone acetate","Abiraterone acetate 1000mg\u002F day",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Dexamethasone","Dexamethasone 0.5mg\u002Fday",[9,16],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Metronidazole","Metronidazole 1500mg\u002F per day",[16],[36],"Flagyl",[38],{"name":39,"affiliation":40,"role":41},"Catherine Handy Marshall, M.D.","Johns Hopkins University","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Donna Bieg, RN","CONTACT","410-502-7635","dieg2@jhmi.edu",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Baltimore","Maryland","21231","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-76.61219,39.29038,{"lat":60,"lon":59},[63],{"name":64,"role":45,"phone":65,"phoneExt":26,"email":66},"Irina Rifkind, RN","410-502-2043","Irifkin1@jhmi.edu",{"type":68,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[70,73],{"name":71,"class":72},"United States Department of Defense","FED",{"name":74,"class":6},"Prostate Cancer Foundation","100563471","phase-2-trial-targeting-gut-bacterial-androgen-production-to-reverse-therapeutic-resistance-to-abiraterone-in-patients-with-metastatic-prostate-cancer-100563471",false,"NCT06616597","Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer","Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer","Inclusion Criteria:\n\n* Males aged 18 years of age and above.\n* Prostate adenocarcinoma\n* Absolute PSA ≥ 2.0 ng\u002FmL at screening.\n* PSA (+\u002F- radiographic) progression after having been on abiraterone and prednisone for at least 12 weeks.\n* Must be maintained on a GnRH analogue or have undergone orchiectomy.\n* Participants must have a life expectancy ≥ 6 months\n* Ability to swallow study medication tablets\n* Willing to abstain from alcohol during and for 14 days after treatment with metronidazole\n* Willing and able to collect urine and stool samples per protocol\n\nExclusion Criteria:\n\n* Active infection or other medical condition that would make dexamethasone use contraindicated\n* Any chronic medical condition requiring a higher systemic dose of corticosteroid\n* Pathological finding consistent with small cell carcinoma of the prostate\n* Has imminent or established spinal cord compression based on clinical findings and\u002For MRI.\n* Chronic liver disease with Child-Pugh class C cirrhosis (see calculator in protocol)\n* Bilirubin \\>3x ULN or AST and ALT \\>5x ULN\n* Congenital prolonged QTc syndrome or QTc \\> 500 msec (non-paced rhythm)\n* History of pituitary or adrenal dysfunction\n* Uncontrolled diabetes (Hemoglobin A1c \\> 10%) or increasing doses of insulin within the past 4 weeks due to poorly controlled glucoses.\n* Administration of an investigational therapeutic or invasive surgical procedure (not including surgical castration) within 30 days of Cycle 1 Day 1 or currently enrolled in an investigational drug study\n* Any other serious illness or medical condition that would, in the opinion of the investigator, make this protocol unreasonably hazardous, including, but not limited to:\n\n  * Any uncontrolled major infection.\n  * Crohn's disease or ulcerative colitis.\n  * Known or suspected toxic megacolon and\u002For known small bowel ileus.\n  * Known allergy to any of the compounds under investigation.\n* On antibacterial therapy within 30 days prior to administration of study treatment.\n* Any condition or situation which, in the opinion of the investigator, would put the subject at risk, or interfere with the subject's participation in this study.","MALE","18 Years",{"count":85,"type":86},58,"ESTIMATED","INTERVENTIONAL",[89],"PHASE2","To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.",[92,93],"Prostate Cancer (Adenocarcinoma)","Metastatic Prostate Cancer",[95,96,28],"Abiraterone","microbiome","2026-02-17",{"date":99,"type":100},"2026-02-19","ACTUAL",{"date":102,"type":100},"2025-02-13",{"date":104,"type":86},"2032-03-30",{"name":5,"class":6},1]